Therapeutic Advances in Hematology

2.9(top 20%)

impact factor

459(top 50%)

papers

7.9K(top 20%)

citations

42(top 20%)

h-index

3.0(top 20%)

impact factor

516

all documents

8.6K

doc citations

64(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Myeloid sarcoma: current approach and therapeutic options	Therapeutic Advances in Hematology	2011	191
2	Factor VIII inhibitors in hemophilia A: rationale and latest evidence	Therapeutic Advances in Hematology	2013	172
3	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products	Therapeutic Advances in Hematology	2019	160
4	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond	Therapeutic Advances in Hematology	2014	151
5	Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence	Therapeutic Advances in Hematology	2015	141
6	Treatment and management of graft-versus-host disease: improving response and survival	Therapeutic Advances in Hematology	2013	140
7	Management of imatinib-resistant patients with chronic myeloid leukemia	Therapeutic Advances in Hematology	2013	108
8	The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development	Therapeutic Advances in Hematology	2011	104
9	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia	Therapeutic Advances in Hematology	2019	93
10	Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma	Therapeutic Advances in Hematology	2012	90
11	New and emerging therapies for acute and chronic graftversushost disease	Therapeutic Advances in Hematology	2018	90
12	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches	Therapeutic Advances in Hematology	2019	90
13	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)	Therapeutic Advances in Hematology	2015	89
14	Comprehensive review of JAK inhibitors in myeloproliferative neoplasms	Therapeutic Advances in Hematology	2013	85
15	Practical aspects of extended half-life products for the treatment of haemophilia	Therapeutic Advances in Hematology	2018	85
16	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment	Therapeutic Advances in Hematology	2011	82
17	Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review	Therapeutic Advances in Hematology	2015	82
18	Gene therapy for hemophilia: what does the future hold?	Therapeutic Advances in Hematology	2018	79
19	The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy	Therapeutic Advances in Hematology	2013	76
20	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?	Therapeutic Advances in Hematology	2019	71
21	Genetic predispositions to childhood leukemia	Therapeutic Advances in Hematology	2013	68
22	Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies	Therapeutic Advances in Hematology	2016	66
23	Novel insights into the treatment of complement-mediated hemolytic anemias	Therapeutic Advances in Hematology	2019	65
24	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia	Therapeutic Advances in Hematology	2019	65
25	Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions	Therapeutic Advances in Hematology	2013	61
26	Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib	Therapeutic Advances in Hematology	2014	57
27	Invasive fungal infections in acute leukemia	Therapeutic Advances in Hematology	2011	56
28	Recognizing familial myeloid leukemia in adults	Therapeutic Advances in Hematology	2013	55
29	Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment	Therapeutic Advances in Hematology	2016	54
30	Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion	Therapeutic Advances in Hematology	2013	53
31	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?	Therapeutic Advances in Hematology	2018	53
32	Targeting the leukemia–stroma interaction in acute myeloid leukemia: rationale and latest evidence	Therapeutic Advances in Hematology	2016	52
33	Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy	Therapeutic Advances in Hematology	2019	52
34	Ovarian vein thrombosis in the nonpregnant woman: an overlooked diagnosis	Therapeutic Advances in Hematology	2012	51
35	Current and emerging factor VIII replacement products for hemophilia A	Therapeutic Advances in Hematology	2017	51
36	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians	Therapeutic Advances in Hematology	2012	50
37	The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia	Therapeutic Advances in Hematology	2018	50
38	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria	Therapeutic Advances in Hematology	2019	50
39	Inherited predisposition to myeloproliferative neoplasms	Therapeutic Advances in Hematology	2013	49
40	Novel agents for the treatment of childhood acute leukemia	Therapeutic Advances in Hematology	2015	49
41	The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia	Therapeutic Advances in Hematology	2016	47
42	Immunotherapy in myeloma: how far have we come?	Therapeutic Advances in Hematology	2019	47
43	Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia	Therapeutic Advances in Hematology	2015	45
44	Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians	Therapeutic Advances in Hematology	2015	43
45	Azacitidine in the management of patients with myelodysplastic syndromes	Therapeutic Advances in Hematology	2012	42
46	Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile	Therapeutic Advances in Hematology	2012	42
47	The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies	Therapeutic Advances in Hematology	2014	42
48	Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis	Therapeutic Advances in Hematology	2017	42
49	Update on the role of lenalidomide in patients with multiple myeloma	Therapeutic Advances in Hematology	2018	42
50	Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia	Therapeutic Advances in Hematology	2019	42

Scientometrics

Overviews

Citing Bodies

Therapeutic Advances in Hematology

Top Articles